Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis.

Fiske CT, Griffin MR, Mitchel E, Sterling TR, Grijalva CG.

Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):666-9. doi: 10.1002/pds.3243. Epub 2012 Apr 24.

2.

A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.

Chung CP, Rohan P, Krishnaswami S, McPheeters ML.

Vaccine. 2013 Dec 30;31 Suppl 10:K41-61. doi: 10.1016/j.vaccine.2013.03.075. Review.

PMID:
24331074
3.

Validation of ICD-9-CM codes to identify gastrointestinal perforation events in administrative claims data among hospitalized rheumatoid arthritis patients.

Curtis JR, Chen SY, Werther W, John A, Johnson DA.

Pharmacoepidemiol Drug Saf. 2011 Nov;20(11):1150-8. doi: 10.1002/pds.2215. Epub 2011 Aug 27.

4.

Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis.

Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell E, Mikuls TR, Saag KG, Singh J, Safford M, Cannon GW.

Arthritis Res Ther. 2011;13(5):R155. doi: 10.1186/ar3471. Epub 2011 Sep 20.

5.

Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.

Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.

J Rheumatol. 2007 Apr;34(4):706-11. Epub 2007 Feb 15.

PMID:
17309133
6.

Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database.

Cho SK, Sung YK, Choi CB, Kwon JM, Lee EK, Bae SC.

Rheumatol Int. 2013 Dec;33(12):2985-92. doi: 10.1007/s00296-013-2833-x. Epub 2013 Aug 6.

PMID:
23918169
7.

Identification of rheumatoid arthritis patients using an administrative database: a Veterans Affairs study.

Ng B, Aslam F, Petersen NJ, Yu HJ, Suarez-Almazor ME.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1490-6. doi: 10.1002/acr.21736.

8.

Validation of rheumatoid arthritis diagnoses in health care utilization data.

Kim SY, Servi A, Polinski JM, Mogun H, Weinblatt ME, Katz JN, Solomon DH.

Arthritis Res Ther. 2011 Feb 23;13(1):R32. doi: 10.1186/ar3260.

9.

Increased risk of mycobacterial infections associated with anti-rheumatic medications.

Brode SK, Jamieson FB, Ng R, Campitelli MA, Kwong JC, Paterson JM, Li P, Marchand-Austin A, Bombardier C, Marras TK.

Thorax. 2015 Jul;70(7):677-82. doi: 10.1136/thoraxjnl-2014-206470. Epub 2015 Apr 24.

PMID:
25911222
10.

Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.

Chiu YM, Lang HC, Lin HY, Yang MT, Fang CH, Yang YW, Schabert VF, Tang B.

Int J Rheum Dis. 2014 Dec;17 Suppl 3:9-19. doi: 10.1111/1756-185X.12539.

PMID:
25496045
11.

An administrative data validation study of the accuracy of algorithms for identifying rheumatoid arthritis: the influence of the reference standard on algorithm performance.

Widdifield J, Bombardier C, Bernatsky S, Paterson JM, Green D, Young J, Ivers N, Butt DA, Jaakkimainen RL, Thorne JC, Tu K.

BMC Musculoskelet Disord. 2014 Jun 23;15:216. doi: 10.1186/1471-2474-15-216.

12.

Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy.

Wolfe F, Michaud K, Anderson J, Urbansky K.

Arthritis Rheum. 2004 Feb;50(2):372-9.

13.

Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada.

Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S.

Arthritis Rheum. 2009 Mar 15;61(3):300-4. doi: 10.1002/art.24476.

14.

Antirheumatic drugs and the risk of tuberculosis.

Brassard P, Kezouh A, Suissa S.

Clin Infect Dis. 2006 Sep 15;43(6):717-22. Epub 2006 Aug 10.

PMID:
16912945
15.

A systematic review of validated methods to capture stillbirth and spontaneous abortion using administrative or claims data.

Likis FE, Sathe NA, Carnahan R, McPheeters ML.

Vaccine. 2013 Dec 30;31 Suppl 10:K74-82. doi: 10.1016/j.vaccine.2013.03.076. Review.

PMID:
24331077
16.

The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.

Winthrop KL, Baxter R, Liu L, McFarland B, Austin D, Varley C, Radcliffe L, Suhler E, Choi D, Herrinton LJ.

Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):229-35. doi: 10.1002/pds.2049. Epub 2010 Dec 10.

17.

Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report.

Malaviya AN, Kapoor S, Garg S, Rawat R, Shankar S, Nagpal S, Khanna D, Furst DE.

J Rheumatol. 2009 Jul;36(7):1414-20. doi: 10.3899/jrheum.081042. Epub 2009 Jun 1.

PMID:
19487263
18.

Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis.

Pehlivan Y, Kisacik B, Bosnak VK, Onat AM.

BMJ Case Rep. 2013 Jan 21;2013. pii: bcr2012006585. doi: 10.1136/bcr-2012-006585.

19.

[Biologics and mycobacterial diseases].

Tsuyuguchi K, Matsumoto T.

Kekkaku. 2013 Mar;88(3):337-53. Japanese.

PMID:
23672175
20.

Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area.

Kim HW, Park JK, Yang JA, Yoon YI, Lee EY, Song YW, Kim HR, Lee EB.

Clin Rheumatol. 2014 Sep;33(9):1307-12. doi: 10.1007/s10067-013-2387-z. Epub 2013 Sep 22.

PMID:
24057090

Supplemental Content

Support Center